Intravitreal topotecan in the management of refractory and recurrent vitreous seeds in retinoblastoma
British Journal of Ophthalmology Aug 30, 2017
Rao R, et al. – The effectiveness of intravitreal topotecan for refractory or recurrent vitreous seeds in retinoblastoma is assessed in this study. Based on these outcomes, three–weekly intravitreal topotecan seems successful and safe in controlling focal or diffuse refractory or recurrent vitreous seeds in retinoblastoma.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
